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Infertility is a complex disorder with significant medical, psychological and financial consequences for patients. With live-birth rates per cycle below 30% and a drive from the Human Fertilisation and Embryology Authority (HFEA) to encourage single embryo transfer, there is significant research in different areas aiming to improve success rates of fertility treatments. One such area is
Introduction
Infertility is a complex disorder with significant medical, psychological and financial sequelae. The Human Fertilisation and Embryology Authority (HFEA) reported that between one in six to one in seven couples in the UK are affected (HFEA, 2013) . While many fertility conditions can be managed without recourse to in vitro fertilization, a significant number of couples will need to use IVF to achieve a pregnancy. In the UK in 2011, 2% of all live births were conceived through IVF (HFEA, 2013 ). An improved understanding of fertility and embryology has allowed the procedures and the techniques to improve, reflected in a steady increase in live-birth rates from assisted reproductive technologies (ART) since the early 90s (HFEA, 2013) . In the UK in 2014 overall pregnancy and live-birth rates per embryo transfer were 36.3% and 26.5%, respectively (HFEA, 2014) . Understandably, there is a drive to further improve these success rates.
The HFEA has identified the high multiple pregnancy rate of ART as a significant public health issue and, as a result, encourages single embryo transfer (SET). In Sweden, the adoption of SET as the standard procedure has resulted in a dramatic decrease in multiple pregnancies and a concomitant improvement in perinatal morbidity and mortality (Kallen et al., 2010; Finnstrom et al., 2011) . However, SET also demands more consistent methods for identifying the best embryo for transfer, as well as improved methods for predicting livebirth.
Currently, parameters known to be associated with the likelihood of live-birth rates are embryo score (Cai et al., 2011; Porcu et al., 2013; Rhenman et al., 2015) , number of previous successful or unsuccessful fertility treatments (Templeton et al., 1996; Nelson and Lawlor, 2011) , female age (Collins et al., 1995; Choi et al., 2013) and endometrial thickness (Kasius et al., 2014; Lebovitz and Orvieto, 2014) . Prediction models have been developed for live-birth after IVF/ICSI treatment and SET, which have found that embryo score, treatment history, total dose of FSH administered, female age, infertility cause, endometrial thickness and female height are all independent predictors of live-birth rate (Vaegter et al., 2017) . A significant amount of research has attempted to identify biomarkers for embryo and oocyte quality. Most of these studies have been targeted analyses, where one class of biological compound is examined for its connection with embryo or oocyte quality (McRae et al. 2012) . Despite this research, currently no definitive biomarkers to predict IVF outcome have been identified. Consequently, studies investigating multiple classes of compounds for their predictive ability of reproductive outcome simultaneously are essential. Altered concentrations of several metabolites together would also make it less likely that the finding has arisen by chance, compared with a single metabolite. Therefore, in recent years research into metabolism and reproductive medicine has moved towards global metabolite profiling, or metabolomics.
Metabolomics
Metabolomics is defined as the non-targeted identification and quantification of all low molecular weight end-products of metabolism (metabolites) (Nicholson et al., 1999) . It reflects events well downstream of gene expression and gives valuable information about the metabolism within cells, that other 'omics' technologies cannot (Allen et al., 2003) . The human genome consists of over 250 000 genes that encode for~200 000 transcripts and over 1 million proteins, whilst in contrast the human metabolome consists of only~3000 metabolites (Fig. 1) . This lower number of metabolites means metabolomic analyses can be performed faster in comparison to genomic and proteomic analyses (Revelli et al., 2009) . Furthermore, transcriptomics and proteomics are limited, providing information only on the effect of a given drug on gene expression, but little information regarding the overall disease response or drug effect since they do not reflect the dynamic metabolic status of the organism (Nicholson et al., 1999) .
The response of an organism's cells to a disease state is to modify the concentrations of numerous metabolites to maintain homeostasis (Lindon et al., 2003) . Metabolites inside the cells of an organism are in dynamic balance with those in the biofluids that perfuse the cells (Nicholson et al., 1999) . Therefore, the effect of an insult should be reflected in an organism's biofluid composition. Eventually it should be possible to distinguish between biofluids from different physiological states, such as diseased and non-diseased, based purely on their metabolic fingerprint.
Immediately after collecting these biofluids, metabolic activity needs to be stopped until the time of analysis, which is achieved by snap freezing in liquid nitrogen and storing the sample at −80°C. The most commonly used analytical platform for metabolomics is nuclear magnetic resonance (NMR) spectroscopy, which calculates the presence of certain nuclei in a sample, most commonly the hydrogen nuclei ( The intensity of the NMR signal on the y-axis is directly related to the concentration of the nuclei giving rise to the signal. Metabolites are small molecules with a small number of given nuclei, and therefore each line along the x-axis represents a particular molecule in the sample. NMR is an ideal platform to analyze biofluids because it is the only method that requires little or no sample preparation, is nondestructive to the sample and requires small sample volumes (Goldsmith et al., 2010) . This is a significant benefit, since often these biofluids are often not available in large volumes. A typical metabolomics procedure is explained in Fig. 2 .
Metabolomics can be applied to reproductive medicine as the causes of subfertility may result in an imbalance of normal metabolism. It is therefore postulated that a better understanding of the metabolic effects of the various aetiologies of infertility may help to improve reproductive outcomes (Baskind et al., 2011) . In addition, it is anticipated that an improved knowledge in this area would lead to the identification of non-invasive biomarkers for diagnostic and prognostic purposes (Baskind et al., 2011) . Biofluid compositions of interest include those used to assess: the quality of the oocytes (follicular fluid, FF), the quality of the embryos (embryo culture medium (ECM) and blastocoele fluid), the implantation capacity of the endometrium (endometrial fluid), the barrier for transport of spermatozoa (cervical mucus) and the overall metabolic status of the patient (blood plasma).
There has been a progression from targeted single metabolite analysis to metabolomics in recent years. The aim of this systematic review is to examine the recent findings for the potential application of metabolomics to female reproduction, specifically to the metabolomics of FF, ECM and endometrial receptivity.
Methods

Search strategy
The systematic search followed PRISMA guidelines (Moher et al., 2009 Figure 1 The 'omics' cascade describes the flow of biological information in an organism.
The search terms and combinations of searches used are listed in Table I . The search was augmented by a snowball strategy, examining the references cited in primary sources and review manuscripts.
Study selection
Given that metabolomics is a relatively recent methodology, no restrictions were placed on publication date and inclusion. Only global metabolic studies analyzing reproductive tract biofluid composition were considered for this review. All single or targeted metabolic studies were excluded from this review, as were those using NMR spectroscopy for structural determination of molecular components from the female reproductive tract. Magnetic resonance imaging and NMR microimaging studies were also excluded. This review aimed to synthesize all available data on the topic, so no studies were excluded because of their design. All English language peer-reviewed human studies were included. However, studies that focused on male subfertility were excluded, as were animal studies, because this review was only investigating the metabolomics of biofluids from the female reproductive tract.
Study screening
After the initial search a total of 3182 records were screened by the first author (T.B-M.) based on the inclusion and exclusion criteria, this process was repeated independently by a second author (S.S.). An overview of the search results and screening process is summarized in the study flow diagram (Fig. 3) . The screening process was cross-checked by a senior author (M-Y.T). Disagreement between the reviewers was resolved by discussion until consensus was reached.
Data extraction
A data extraction spreadsheet was developed and agreed between the authors. The selected studies were comprehensively examined and relevant data were extracted for each paper and inputted to the spreadsheet by the first author (T.B-M.) then cross-checked by the second author (S.S). The information selected included author details, year of publication and country of the study, study aim, sample size, methodology, sample characteristics, outcome measures and a summary of findings. Disagreements regarding extracted data were resolved by discussion and deliberated on by the most senior authors (E.H., M.J. and M-Y.T.). The systematic review was not registered.
Quality assessment of the included studies
Two authors (T.B-M. and S.S.) independently assessed the risk of the included studies. All randomized controlled trials (RCTs) included in this systematic review were evaluated for risk of bias using Cochrane's tool for the 'risk of bias' assessment (Higgins and Green, 2012) . This tool comprises the Figure 2 Flow diagram demonstrating a typical metabolomic procedure. Sample collection (1) shows ultrasound guided aspiration of follicular fluid (FF) in this example. Following NMR analysis (2) the spectral data are reduced (3). A common method of data reduction is 'binning', which involves dividing the spectrum into regions of equal width and calculating the area under the signals within each region (3). After data reduction, multivariate analysis can be performed in order to look at differences in spectral data (4). Principal components analysis (PCA) is a commonly used multivariate analysis method. The analysis produces a scores plot and loadings plot which can be used to identify trends across a set of patients (Baskind et al., 2011). following categories: (i) random sequence generation; (ii) allocation concealment; (iii) blinding of participants and personnel; (iv) blinding of outcome assessment; (v) incomplete outcome data; (vi) selective reporting; and (vii) other sources of bias. Each category had three outcomes: low bias risk, high bias risk and 'unclear' risk of bias, when the study gave insufficient information to assess bias.
The methodological quality of the observational studies were assessed using the ROBINS-I tool (Sterne et al., 2016) . This assessment includes three categories: pre-intervention, at intervention and post-intervention. Each category is assessed as 'low risk of bias', 'moderate risk of bias', serious risk of bias, 'critical risk of bias' and 'no information'.
Results
Search strategy and study selection
After the initial search, a total of 3182 records were screened. The publications screened dated from 1991-2016. Following an initial screen, 2814 studies were excluded due to the title alone and 368 abstracts were retained and examined. This resulted in the exclusion of 331 abstracts that were not relevant to the research question (e.g. targeted metabolic analysis), different research population (e.g. male fertility patients, animals) not available in English, or duplicate studies. Four papers were included after snowball strategy of other relevant studies. Of the 41 full text publications that were examined, 21 met the inclusion criteria. Of the 20 studies that were excluded, 13 were review or opinion articles, 5 were duplicate studies and 2 were unavailable in English. An overview of the search results and screening process is summarized in the study flow diagram (Fig. 3) .
Study characteristics
Data from the 21 studies included in this review showed considerable variation regarding the research question, methodology, study design, sample size and outcome measures. The characteristics of the 21 included studies is divided into those investigating metabolomics and FF (Table II) , studies investigating metabolomics and ECM (Table III) , and studies investigating metabolomics and other biofluids in the female reproductive tract (Table IV) . Of the metabolomics studies identified, thirteen were performed on ECM, five were on FF, one was on blastocoele fluid, one was on oocyte culture medium and one was on endometrial fluid. Tables II-IV include information on the author, date of study, country of origin, sample and method, study aim, study findings and conclusion of the study Fig. 3 .
The mean samples size over all the studies was 144, ranging from 10 (McRae et al., 2012) to 485 patients (Seli et al., 2010a,b) . Of the 21 studies, the highest number were conducted in the USA (6), followed by Holland (3), Spain (3), UK (2), Sweden (2), France (1), Belgium (1), China (1), Denmark (1), France (1), Greece (1) and Italy (1). Considering the list of countries of the included studies, a bias towards western populations is evident as these studies are overrepresented in the review sample. A further bias is the fact that only studies published in English language journals, or where a translation was available, were included in the review.
Synthesis of results
The pooled results are reported in Tables II-IV as described above. The risk of bias of the RCTs is reported in Categories of studies (1) Global metabolomics studies of follicular fluid (2) Global metabolomics studies of embryo culture medium (3) Global metabolomics studies of endometrial receptivity (4) Global metabolomics studies of cervical mucous/ovarian tissue reported in Table VI . The pilot studies were not assessed for risk of bias.
Discussion
A significant amount of knowledge has been gained in recent decades on the metabolic profile of female reproductive tract fluids by the from targeted metabolic analysis of ECM, FF and blood plasma, however no single biomarker has been identified, presumably because the metabolic picture is far more complex than that which can be explained by a single metabolite imbalance. Therefore, in recent years there has been a move to global metabolomic analysis. Infertility is a significant problem with multiple aetiologies, where sophisticated modern metabolomic techniques have the potential to provide valuable insights. A more comprehensive understanding of the reproductive tract environment and nutritional status of the developing oocyte and embryo will have significant benefits for diagnosis and therapy in the field of fertility. This systematic review has revealed the paucity of data and inconsistencies in the literature regarding metabolomic studies in the field of fertility, as well as a lack of research examining the effects of various gynecological diseases, such as polycystic ovary syndrome, pelvic inflammatory disease and endometriosis.
Follicular fluid
The FF is the in vivo microenvironment for a developing oocyte and has to contain all the components that are essential for follicular growth and oocyte maturation and as the metabolites excreted by the oocytes as well as the granulosa cells, which are likely to be a far greater contributor than the oocyte. It is possible that the metabolic make up of FF could reflect oocyte quality. FF is easily obtained in IVF patients, since it is aspirated at the time of oocyte collection and discarded. Numerous studies have performed targeted analyses of low molecular weight molecules in the FF and have failed to identify any clinically useful biomarker (Revelli et al., 2009) .
The use of FF as a biomarker for potential outcome in assisted reproduction has some significant limitations in its current state. First, and perhaps the biggest limitation, is that for patients who have two embryos transferred, unless a non-identical twin pregnancy ensues, it 79 abstracts were unavailable 217 were not in English 186 were duplicate studies 2332 were irrelevant studies 54 were not in English 89 were duplicate studies 188 were irrelevant studies Full text articles excluded, with reasons (n = 20) 2 texts were not available in English 5 were duplicate studies 13 were reviews or opinion articles is not possible to know which embryo successfully implanted and therefore the FF cannot be linked to IVF outcome. This means for the purpose of biomarker identification, FF samples need to be obtained from women undergoing SET, which decreases the potential recruitment of patients significantly. Second, some patients seeking fertility treatment may have unique metabolic profiles that could affect the discrimination between profiles from good and bad quality oocytes. Third, the process of ovarian stimulation can alter the composition of FF (de los Santos et al., 2012) , and therefore women should be on the same IVF drug regimen or be undergoing naturalcycle IVF. Fourth, there is potential for FF contamination with the flushing medium used by some centers during the oocyte collection process. Flushing medium contain numerous metabolites, such as glucose, meaning that a FF sample contaminated by a variable No correlation between metabolomics profile and pregnancy outcome, therefore unable to develop a model for prediction of pregnancy. There was a high degree of individual variation in the metabolome that had no relation to pregnancy outcome.
The study questions the usefulness of the entire metabolome for embryo selection, which should direct the search for viability markers in the culture media towards individual components.
Marhuenda-Egea et al. (2010) Spain
Case control study. ECM from embryos that implanted successfully (n = 10), and in those that failed to implant (n = 15). A classification chemometric tool, SIMCA was used, to classify samples as 'pregnancy' or 'non-pregnancy' based on amino acid concentrations HPLC-MS.
To investigate if there are any metabolomics differences in embryos that implanted successfully and in those failing to implant. ) were then analyzed by observers blinded to pregnancy outcome and embryo morphology using the algorithm generated in the training set. NIR spectroscopy.
To evaluate whether the viability score alone, or in combination with embryo morphology, was a better predictor than morphology alone for IVF outcome.
AUC was greater for the metabolomic Viability Score compared to morphology alone.
The viability score alone, or in combination with morphological grading is a better predictor of IVF outcome than morphology alone.
Sfontouris et al. 
Continued
proportion of flushing medium would not represent the true metabolic make up of the FF. FF from the previously aspirated follicle also has the potential to contaminate the aspirate of the next follicle collected. This highlights that research surrounding metabolomics analysis of FF is in its infancy, and more studies are needed before the true potential of global metabolomics profiling of FF are realized. Such studies should take into account the above challenges, and ideally study the FF from natural-cycle IVF patients with no drug regimens and who undergo SETs with no flushing medium used. Natural cycles in particular are rare, and these limitations mean it would take a long time to obtain the required number of samples to generate statistically significant findings. The studies included in this review revealed the potential for the metabolomics assessment of FF to predict the outcome of fertility treatment, however the data is inconsistent and the numbers included in the studies were small (Table II) .
Embryo culture medium
In clinical practice today, embryos are selected as suitable for transfer based on morphological assessment and cleavage rates (Sakkas and Gardner, 2005) . These assessments are quick and economical, but have limited predictive value, significant inter-observer variability and do not detect genetic abnormalities (Singh and Sinclair, 2007) . In response to this, a morphokinetic model was developed, allowing automated assessment of various parameters over time, and was found to predict embryos most likely to develop into blastocysts (Meseguer et al., 2011; Cruz et al., 2012) . Biomarkers for embryo quality could overcome some of the weaknesses of morphological assessment and, although unlikely to replace them, could certainly complement them.
ECM studies have indicated that metabolic differences between embryos could indicate their potential to successfully implant, however its application to the clinical setting has numerous hurdles . First, and most significantly, the three RCTs included in the review all found that the addition of metabolomics profiling of ECM to morphology does not improve the chance of achieving a viable pregnancy when compared to using morphology alone (Hardarson et al., 2012; Vergouw et al., 2012a,b; Sfontouris et al., 2013) . Considering that these are the highest quality studies reviewed (Tables V and VI) , this is of great significance in showing metabolomics profiling of ECM does not currently have a clinical role in the field of fertility. Second, the studies described above used ECM that were frozen at the point of collection, and then transported to a central laboratory. Metabolomic profiling has not been shown to be a reproducible, robust test when performed at local sites (Hardarson et al., 2012) . Third, fertility clinics use different types and volumes of embryo culture media, and have differing practices in terms of timing of embryo transfer. Whether metabolomic profiling is influenced by these factors needs further study. Finally, aneuploidy is an important factor in failed implantation and miscarriage, and whether aneuploidy will have a unique and detectable metabolomic profile requires further investigation (Seli et al., 2010a,b) .
Metabolomics has the potential to identify numerous biomarkers concurrently and its eventual aim, with regard to embryo assessment, is to produce a model that generates a robust non-subjective scoring system, eliminating the need for expert opinion. Additionally, if only a small number of predictive biomarkers were to be identified, it may be possible to develop simple, rapid and cheap tests that could be performed in each fertility center. ECM, embryo culture medium; SET, single embryo transfer; NIR spectroscopy, near infrared spectroscopy; RCT, randomized controlled trial; SIMCA, soft independent modeling of class analogy; HPLC-MS, high performance liquid chromatography mass spectrometry; AUC, area under the curve; IR, implantation rate; FHA, fetal heart activity.
The endometrium
The human endometrium is a dynamic tissue that is receptive for implantation for a short period of time during the natural menstrual cycle, known as the 'window of implantation' (WOI) (Harper, 1992) . This window varies according to different menstrual cycle lengths, but occurs in the mid-secretory phase, coinciding with Days 19-21 of a normal length cycle (Bergh and Navot, 1992) . Investigating new molecules that can predict the presence or absence of the WOI and its timing would have significant implications for fertility treatment (Berlanga et al., 2011) . Studies have investigated cytokine profiles at different points in the menstrual cycle (Simon et al., 1993; Dominguez et al., 2008; Boomsma et al., 2009) , as well as proteomic profiles of the endometrial fluid (Casado-Vela et al., 2009) in an attempt to detect functional changes in the endometrium during the menstrual cycle by non-invasive methods. One of the main problems with these techniques is that a biopsy is essential for analysis, necessitating waiting until the next cycle to transfer the embryo. However, endometrial fluid can be aspirated without impacting implantation or pregnancy rates in the same cycle, and this means that a metabolomic analysis of the endometrium could be carried out in the same cycle as an embryo transfer (van der Gaast et al., 2003) . Metabolomics certainly lags behind other 'omics' technologies with regard to studying endometrial receptivity, with only one pilot study identified investigating endometrial fluid (Vilella et al., 2013) . Identifying biomarkers associated with endometrial receptivity is clearly desirable and could significantly impact pregnancy rates in patients seeking reproductive treatments.
Limitations of the current evidence
Metabolomics has the potential to reveal previously unknown influences on fertility. However, this research methodology is in its early stages, and several hurdles have to be overcome before useful biomarkers are in routine clinical practice. Metabolism is a dynamic process, therefore obtaining samples over time enhances its ability to provide mechanistic insights into a disease process. It remains to be clarified whether metabolomic studies can detect epigenetic changes, which may impact embryo implantation, early pregnancy development and may negatively impact fetal development. Metabolomic studies have currently focused on oocyte and embryo quality by studying FF and ECM, respectively. One study also demonstrated that fluid could be withdrawn from a blastocyst cavity prior to cryostorage, therefore making a direct metabolic assessment of the embryo (D'Alessandro et al. Serious risk: the study is judged to be at serious risk of bias in at least one domain, but not at critical risk of bias in any domain.
on the general health of the individual, and it therefore follows that metabolomics assessment of blood plasma could be very useful as a supplementary test in fertility patients, although it is unlikely to ever be the only investigation required for global metabolic fertility assessment. Finally, the majority of the studies were observational and were at serious risk of bias, meaning that the quality of evidence of the included studies was generally poor. The best available evidence comes from the two RCTs judged to be at low risk of bias, and these studies observed that metabolomics of ECM is not able to improve reproductive outcomes.
Conclusion
A range of sophisticated modern metabolomic techniques are now more widely available and have been applied to the analysis of the female reproductive tract. However, this review has revealed the paucity of metabolomic studies in the field of fertility, the inconsistencies of findings between different studies, as well as a lack of research examining the metabolic effects of various gynecological diseases. In the future, larger scale studies are required to investigate the ability of metabolomic profiles of these relevant biofluids to predict the outcome of fertility treatment. These should then be followed up with large multi-center RCTs to assess, for example, whether embryo selection with metabolomics versus standard embryo selection improves ART outcomes. In addition, few metabolomic studies have investigated and compared the metabolic profiles of different fertility patient groups, such as those with unexplained infertility, tubal infertility, recurrent failed IVF and recurrent spontaneous miscarriage. Infertility is a complicated problem with multiple aetiologies. There is currently no evidence that metabolomics profiling can improve fertility outcomes. However, metabolomics could provide a more comprehensive understanding of the nutritional status of the developing oocyte and embryo, as well as the environment within the reproductive tract. This has potential implications for diagnostics as well as improvements the outcome of fertility treatment in the future.
